Sofregen Medical

Sofregen Medical is a private biotechnology company leveraging a proprietary silk protein platform to create a portfolio of implantable and injectable biomaterials for soft tissue regeneration. Founded in 2013 and headquartered in Medford, Massachusetts, the company has two FDA-cleared products: SERI® Surgical Scaffold and Silk Voice® Injectable Implant. Sofregen is advancing its pipeline to develop next-generation silk-based fillers and devices for the aesthetic and reconstructive surgery markets, aiming to become a leader in regenerative beauty solutions.

Proprietary platform based on highly purified silk protein (fibroin). The technology engineers silk into various forms (e.g., surgical scaffolds, porous particles for injection) that are biocompatible, resorbable, and designed to facilitate cellular infiltration and tissue regeneration.

In aesthetics, Sofregen would compete against giants like Allergan (Juvéderm), Galderma, and Merz, which dominate the filler market with hyaluronic acid and other products. In surgical scaffolds, it faces competition from other biologic mesh products. Its differentiation hinges on the unique regenerative properties of its silk protein platform.